Biomarkers for immune checkpoint inhibitors--authors' reply

Affiliations

¹ Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, 53100 Siena, Italy.
² Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, 53100 Siena, Italy. Electronic address: mmaiocro@gmail.com.

Comment

Luana Calabrò et al. Lancet Oncol. 2014 Jan.

. 2014 Jan;15(1):e1-2.

doi: 10.1016/S1470-2045(13)70573-4.

¹ Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, 53100 Siena, Italy.
² Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, 53100 Siena, Italy. Electronic address: mmaiocro@gmail.com.

No abstract available

Comment on

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M. Calabrò L, et al. Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11. Lancet Oncol. 2013. PMID: 24035405 Clinical Trial.
Biomarkers for immune checkpoint inhibitors.
Lievense LA, Hegmans JP, Aerts JG. Lievense LA, et al. Lancet Oncol. 2014 Jan;15(1):e1. doi: 10.1016/S1470-2045(13)70557-6. Lancet Oncol. 2014. PMID: 24384488 No abstract available.